Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
September 25, 2024 7:15 AM
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $1,242.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
